AlloVir (ALVR)
(Delayed Data from NSDQ)
$0.79 USD
-0.03 (-3.78%)
Updated May 10, 2024 04:00 PM ET
After-Market: $0.78 -0.01 (-0.70%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALVR 0.79 -0.03(-3.78%)
Will ALVR be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ALVR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALVR
Are Medical Stocks Lagging AlloVir (ALVR) This Year?
Down -72.39% in 4 Weeks, Here's Why You Should You Buy the Dip in AlloVir, Inc. (ALVR)
ALVR: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Stocks With Rising P/E to Bet on for Solid Gains
5 Top-Ranked Stocks With Rising P/E Worth Investing In
Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%
Other News for ALVR
Maintaining a Hold: AlloVir’s Strategic Uncertainty and Financial Outlook
ALVR Stock Earnings: AlloVir Misses EPS for Q4 2023
SHAREHOLDER ALERT: Potential Recovery for AlloVir, Inc. (ALVR) Investors
AlloVir Faces Delisting Risk, Considers Reverse Split to Comply